Pharmaceutical Market Entry
Services in Malaysia

A note on terms: NPRA officially calls the holder the Product Registration Holder (PRH). Throughout RHMI's guides we use the equivalent international term, Marketing Authorisation Holder (MAH) - they mean the same party.

What we do

Every foreign manufacturer entering Malaysia has to solve the same four problems: the product must be registered with NPRA, a locally incorporated entity must hold that registration, the product must be imported under licence, and it must be distributed under Good Distribution Practice. Most manufacturers solve all four by handing everything to a distributor - and discover later that their market access sits in someone else's name.

RHMI solves the same four problems without that trade-off. We are not a consultancy that writes you a report and leaves; we act as the local structure itself - and the terms that protect your control are written into the agreement before anything is filed.

Our services

Marketing Authorisation Holder (MAH) services

The core of what we do. RHMI acts as the independent holder of your Malaysian product registration, so your market access is not tied to your commercial partner. You keep ownership of the dossier and data, your right to move the registration is fixed in the contract, and renewals and an exit process are agreed up front.
MAH services in detail →

Product registration with NPRA

We assess which route your existing approval opens, convert the dossier to ACTD, file in QUEST3+ and manage NPRA correspondence through to the MAL number - including the reliance routes that shorten the review for products approved by recognised agencies.
Product registration in detail →

Regulatory and market entry consulting

For manufacturers who are not ready to file yet. Route and eligibility assessment, dossier gap analysis, realistic timelines, and advice on structuring the holder, import and distribution roles so you keep control.
Consulting in detail →

Import and distribution

Registration alone puts nothing on a shelf. We coordinate licensed import and GDP-compliant distribution through the channel that fits your product - while the registration stays independent of any single commercial partner.
Import & distribution in detail →

Market entry by region

Where you are entering from changes your starting position: which reliance route is open, whether your dossier format converts, how your GMP status is treated.
Market entry guides → - Europe, North America, South America, Asia

Medicine shortage and urgent supply

When a medicine is in shortage in Malaysia, we help connect manufacturers that have stock or capacity with the urgent demand - within the regulatory framework that applies to such situations.
Shortage & urgent supply →

How an engagement works

1. Scoping call. You tell us the product, the approving regulator, the approval date and the GMP standing of your sites. Twenty minutes is usually enough to tell you whether a full route assessment is worth doing for this product.
2. Route assessment. We come back with the registration route your product qualifies for, a realistic timeline, and the structure we recommend for holder, import and distribution.
3. Agreement. The contract fixes what protects you - dossier ownership, transfer rights, renewal terms and the exit process - before anything is filed.
4. Execution. We file, respond to NPRA, and take the product through to registration, import and first sale, with a named contact and regular status updates.

Start with a scoping call →

Why manufacturers choose an independent structure

The convenient path - letting the distributor hold the registration - ties your market access to one commercial relationship. If it sours, the registration sits in your former partner's name, and moving it requires their consent. RHMI was built to provide the alternative: the holder is independent of the commercial channel, and your control is contractual, not a matter of goodwill. The lock-in risk, in detail.

Frequently asked questions

Can RHMI hold our product registration without being our distributor?

Yes - that is the core of the model. RHMI acts as an independent Marketing Authorisation Holder, and distribution is structured separately through the channel that fits your product. The registration is not tied to any single commercial partner.

What does it cost?

It depends on the product category, the registration route and the scope of the engagement. The initial scoping call costs nothing; the formal route assessment is priced by portfolio size. After it we give a fixed proposal - you know the full cost structure before you commit to execution.

How long does registration take?

It depends on the route your existing approval opens: verification review targets 30 working days, abbreviated review 90 working days, the FDA/EMA recognition pilot 60 working days, and full evaluation takes substantially longer. These are NPRA administrative targets, not guarantees. The route assessment tells you which one applies to your product.

Can you take over a registration currently held by our distributor?

Yes. Malaysia has a formal change-of-holder procedure that keeps your MAL number. The application is filed by the current holder, so the transfer needs their cooperation - which is exactly why exit terms belong in the contract from day one. We manage the process, and the registration then sits with an independent holder. How the change of MAH works.

You might also find useful

• Marketing Authorisation Holder (MAH) in Malaysia: What It Is and How to Appoint One
• Distributor as Your MAH in Malaysia: Lock-in Risk and How to Keep Control
• Drug Registration in Malaysia: Process, Timeline and Requirements

• Editorial note: This page describes RHMI's services for manufacturers evaluating Malaysia. Regulatory timelines, fees and eligibility are administrative details that change; we confirm them against NPRA's current guidance in every engagement. Last reviewed: 1 September 2026.